RTW INVESTMENTS LP
Q2 2024 Form 13-F
NEW YORK, NEW YORK
CIK 0001493215
· CRD 153232
· SEC-registered investment adviser
$6.5B Reported Value Total
RTW INVESTMENTS LP reports 10 total accounts under management (AUM). There are 10 discretionary accounts valued at $8,820,485,054, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $13.7B gross asset value
Hedge Fund: $13.4B · Private Equity Fund: $284.4M
Source: Form ADV filed 2026-03-30
Reported value
$6.5B
Quarter over quarter
-9.1%
Holdings
68
Top-10 concentration
48.8%
Filing Structure
Reports holdings for
- RTW MASTER FUND LTD · File #028-16671 · Q4 2014 – Q2 2023 · declared by one filing
- RTW Innovation Master Fund Ltd · File #028-19525 · Q1 2019 – Q2 2023 · declared by one filing
- RTW Venture Fund Ltd · File #028-19571 · Q2 2019 – Q2 2023 · declared by one filing
- RTW Special Purpose Fund II, LLC (not a 13F filer in our records) · File #028-19631 · Q3 2019 – Q4 2020
Key People
Form ADV owners & control persons
Roderick Tze Ian Wong
MANAGING PARTNER, CHIEF INVESTMENT OFFICER
Naveen Yalamanchi
PARTNER, PORTFOLIO MANAGER
Robert John Aurigema
PARTNER, CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $6.5B |
| Positions | 68 |
| Change in reported value | -4.7% |
| New positions | 7 |
| Exited positions | 8 |
| Position turnover | 19.7% |
| Top-10 concentration | 48.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
84 | $11.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
88 | $10.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
91 | $10.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
74 | $8.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
73 | $7.0B |
|
Q1 2025 13F
Filed May 15, 2025
|
68 | $6.5B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
72 | $6.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
68 | $6.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
68 | $6.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
69 | $6.8B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
64 | $6.4B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
67 | $4.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
62 | $5.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
60 | $4.8B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
77 | $4.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
85 | $4.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
107 | $3.9B |
|
Q1 2022 13F
Filed May 16, 2022
|
106 | $4.8B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
124 | $6.8B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
120 | $6.6B |
27 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MDGL MADRIGAL PHARMACEUTICALS INC | $536.7M | 8.31% |
| 2 | RCKT ROCKET PHARMACEUTICALS INC | $380.8M | 5.9% |
| 3 | AXSM AXSOME THERAPEUTICS INC | $373.1M | 5.78% |
| 4 | RNA AVIDITY BIOSCIENCES INC | $359.8M | 5.57% |
| 5 | ARGX ARGENX SE | $281.4M | 4.36% |
| 6 | NTRA NATERA INC | $280.8M | 4.35% |
| 7 | MRUS MERUS N V | $246.7M | 3.82% |
| 8 | INSM INSMED INC | $243.9M | 3.78% |
| 9 | PTCT PTC THERAPEUTICS INC | $226.1M | 3.5% |
| 10 | DYN DYNE THERAPEUTICS INC | $225.4M | 3.49% |
| 11 | ACAD ACADIA PHARMACEUTICALS INC | $222.7M | 3.45% |
| 12 | BRKR BRUKER CORP | $219.8M | 3.4% |
| 13 | MASI MASIMO CORP | $184.2M | 2.85% |
| 14 | PTGX PROTAGONIST THERAPEUTICS INC | $183.2M | 2.84% |
| 15 | ALKS ALKERMES PLC | $170.1M | 2.63% |
| 16 | IMCR IMMUNOCORE HLDGS PLC | $165.0M | 2.56% |
| 17 | CYTK CYTOKINETICS INC | $147.4M | 2.28% |
| 18 | RARE ULTRAGENYX PHARMACEUTICAL IN | $134.0M | 2.07% |
| 19 | PEN PENUMBRA INC | $133.6M | 2.07% |
| 20 | AKRO AKERO THERAPEUTICS INC | $127.4M | 1.97% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.